REIG JOFRE publishes its 2025 nine-months financial results
REIG JOFRE REPORTS €242M IN REVENUE FOR THE FIRST NINE MONTHS AND ADVANCES ITS INDUSTRIAL AND BIOTECH TRANSFORMATION
- Revenue 9M 2025: €242 M (–4%), in a year of transition due to lower temporary production of antibiotics.
- Reported EBITDA: €24 M (margin 10%); pro forma EBITDA: €33 M (+2%), reflecting the strength of recurring business.
- Net result: €1.9 M, including the contribution from Syna Therapeutics and the increase in ownership in Leanbio to 47%
- Industrial ramp-up in Toledo and Barcelona, with recovery expected from 2026 as new capacities come online.
- Innovation and biotech integration: early collection of 100% of the IPCEI Med4Cure/EMINTECH grant (€13M) and deeper integration of Leanbio within the group.
- Business units: Specialty Pharmacare (+1%) and Consumer Healthcare (+3%) partially offset the impact on Pharmaceutical Technologies.
- International footprint: international sales accounted for 58% of total revenue, supported by commercial growth and the consolidation of own brands.
- Financial strength: DFN/EBITDA at 2.1x, gross margin at 61%, operating cash flow of €5.0 M and market capitalization of €230 M.
- Scrip Dividend: 98% of shareholders chose to receive new shares, strengthening equity without impacting cash.
REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish stock market, closed the first nine months of 2025 with revenues of €242 million, down 4% compared to the same period in 2024 -or up 3% on a like-for-like basis excluding the antibiotics portfolio- in a year marked by industrial investments, operational optimisation and international expansion. The company is progressing according to its strategic plan, laying the foundations for progressive improvement in productivity and profitability from 2026 onwards.
Reported EBITDA reached €24 million (margin of 10%), affected by lower temporary production of antibiotics in Toledo during the phase of production improvements and adaptation to Annex 1 of the EU GMP. The figure includes the EMINTECH grant, with a net impact of €1.0 million. On a comparable basis, proforma EBITDA reached €33 million (+2%), excluding the temporary capacity reduction in antibiotics, the effects of EMINTECH, and other biotechnology developments—highlighting the resilience of the core business and the greater contribution from higher-margin divisions.
Net income amounted to €1.9 million and includes the contribution from equity-accounted affiliates: 50% of Syna Therapeutics and 47% of Leanbio S.L. —up from 24% in 3Q25— in line with the company’s strategy to vertically integrate biotechnological API production in the new facility under construction.